GEN Exclusives

More »

GEN News Highlights

More »
Sep 17, 2009

RainDance and CLC bio Partner to Provide Software for Targeted Resequencing

  • RainDance Technologies and CLC bio are working together to develop software for the analysis of targeted resequencing data generated by workflows incorporating next-generation DNA sequencing platforms and RainDance’s Sequence Enrichment Solution.

    As a first step, CLC bio will release an expansion to its CLC Genomics Workbench. This will reportedly enable scientists to analyze data faster and more effectively when using the RainDance solution for large-scale, targeted resequencing studies. The software is already in use by RainDance scientists and will be released for commercial sale later this month.

    “The rapid and efficient analysis of genomic data plays an important role in searching for the variants in large populations that cause cancer and other devastating diseases,” remarks Christopher McNary, president and CEO, RainDance Technologies. “By partnering with CLC bio, we can provide researchers with a solution that leverages the power of our innovative microdroplet-based technology to provide the highest quality results in a simple yet powerful workflow.”

    CLC bio and RainDance say that the combined solution can be used with any next-generation sequencing workflow, giving customers the freedom to choose between the Illumina Genome Analyzer, Roche/454, or Applied Biosystems SOLiD system.

    In the future, the partnership will release specialized reports, data analyses, and workflow support for platform-independent targeted resequencing research.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »